Proactive Investors - Run By Investors For Investors

Admedus in trading halt with sale transaction news pending

The trading halt will remain in place until an announcement is made or until the beginning of trade on April 12, 2019.
Admedus in trading halt with sale transaction news pending
Shares last traded at 9.2 cents per share

Admedus Ltd (ASX:AHZ) is in a trading halt pending an announcement regarding an Admedus Immunotherapies sale transaction and a response to price query from the ASX.

The company’s securities will remain in trading halt until Friday April 12, 2019 or when the announcement is made to market.

READ: Admedus delivers results with heart-driven corporate strategy

Early last month Admedus received regulatory approval in the form of the CE Mark for its CardioCel 3D product portfolio and its collagen bioscaffold VascuCel in Europe.

The company intends to begin the first phase of its commercial launch of CardioCel 3D after having worked with selected key opinion leaders familiar with the technology.

View full AHZ profile View Profile

Admedus Ltd Timeline

Related Articles

February 01 2019
The cancer detection device is on track to finish a key clinical study in the first quarter of 2019, but in the meantime, it has shown promise in detecting abnormalities in unborn children
Challenge trials can speed up vaccine development
May 30 2019
The challenge trial charts the entire disease life cycle from healthy to sick and back to health.
A man's knee pain is highlighted with a red area that points to inflammation
January 23 2019
The injectable PPS trial has had a clinically meaningful and statistically significant result in patients with arthritic knee pain.

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use